There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alvotech (ALVO – Research Report), Cardinal Health (CAH – Research Report) and Lexicon Pharmaceuticals (LXRX – Research Report) with bullish sentiments.
Alvotech (ALVO)
Barclays analyst Balaji Prasad maintained a Buy rating on Alvotech today and set a price target of $20.00. The company’s shares closed last Monday at $13.33.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of
Alvotech has an analyst consensus of Moderate Buy, with a price target consensus of $24.00.
See today’s best-performing stocks on TipRanks >>
Cardinal Health (CAH)
Barclays analyst Stephanie Davis assigned a Buy rating to Cardinal Health today and set a price target of $117.00. The company’s shares closed last Monday at $102.83.
According to TipRanks.com, Davis is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cardinal Health with a $115.14 average price target.
Lexicon Pharmaceuticals (LXRX)
In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Lexicon Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Monday at $1.71.
According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lexicon Pharmaceuticals with a $7.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALVO:
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
- Alvotech signs agreement with Teva to bring Adalimumab-ryvk to U.S. market
- Alvotech management to meet virtually with Northland
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
